tetano
Editor, Senior Moderator
PLoS One
. 2020 Nov 9;15(11):e0242045.
doi: 10.1371/journal.pone.0242045. eCollection 2020.
A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19
Yongsheng Huang[SUP] 1 [/SUP], Xiaoyu Lyu[SUP] 2 [/SUP], Dan Li[SUP] 3 [/SUP], Lin Wang[SUP] 1 [/SUP], Yujun Wang[SUP] 4 [/SUP], Wenbin Zou[SUP] 5 [/SUP], Yingxin Wei[SUP] 6 [/SUP], Xiaowei Wu[SUP] 5 [/SUP]
Affiliations
Abstract
Coronavirus Disease 2019 (COVID-19) has recently become a public emergency and a worldwide pandemic. However, the information on the risk factors associated with the mortality of COVID-19 and of their prognostic potential is limited. In this retrospective study, the clinical characteristics, treatment and outcome data were collected and analyzed from 676 COVID-19 patients stratified into 140 non-survivors and 536 survivors. We found that the levels of Dimerized plasmin fragment D (D-dimer), C-reactive protein (CRP), lactate dehydrogenase (LDH), procalcitonin (PCT) were significantly higher in non-survivals on admission (non-survivors vs. survivors: D-Dimer ≥ 0.5 mg/L, 83.2% vs. 44.9%, P<0.01; CRP ≥10 mg/L, 50.4% vs. 6.0%, P<0.01; LDH ≥ 250 U/L, 73.8% vs. 20.1%, P<0.01; PCT ≥ 0.5 ng/ml, 27.7% vs. 1.8%, P<0.01). Moreover, dynamic tracking showed D-dimer kept increasing in non-survivors, while CRP, LDH and PCT remained relatively stable after admission. D-dimer has the highest C-index to predict in-hospital mortality, and patients with D-dimer levels ≥0.5 mg/L had a higher incidence of mortality (Hazard Ratio: 4.39, P<0.01). Our study suggested D-dimer could be a potent marker to predict the mortality of COVID-19, which may be helpful for the management of patients.
. 2020 Nov 9;15(11):e0242045.
doi: 10.1371/journal.pone.0242045. eCollection 2020.
A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19
Yongsheng Huang[SUP] 1 [/SUP], Xiaoyu Lyu[SUP] 2 [/SUP], Dan Li[SUP] 3 [/SUP], Lin Wang[SUP] 1 [/SUP], Yujun Wang[SUP] 4 [/SUP], Wenbin Zou[SUP] 5 [/SUP], Yingxin Wei[SUP] 6 [/SUP], Xiaowei Wu[SUP] 5 [/SUP]
Affiliations
- PMID: 33166991
- DOI: 10.1371/journal.pone.0242045
Abstract
Coronavirus Disease 2019 (COVID-19) has recently become a public emergency and a worldwide pandemic. However, the information on the risk factors associated with the mortality of COVID-19 and of their prognostic potential is limited. In this retrospective study, the clinical characteristics, treatment and outcome data were collected and analyzed from 676 COVID-19 patients stratified into 140 non-survivors and 536 survivors. We found that the levels of Dimerized plasmin fragment D (D-dimer), C-reactive protein (CRP), lactate dehydrogenase (LDH), procalcitonin (PCT) were significantly higher in non-survivals on admission (non-survivors vs. survivors: D-Dimer ≥ 0.5 mg/L, 83.2% vs. 44.9%, P<0.01; CRP ≥10 mg/L, 50.4% vs. 6.0%, P<0.01; LDH ≥ 250 U/L, 73.8% vs. 20.1%, P<0.01; PCT ≥ 0.5 ng/ml, 27.7% vs. 1.8%, P<0.01). Moreover, dynamic tracking showed D-dimer kept increasing in non-survivors, while CRP, LDH and PCT remained relatively stable after admission. D-dimer has the highest C-index to predict in-hospital mortality, and patients with D-dimer levels ≥0.5 mg/L had a higher incidence of mortality (Hazard Ratio: 4.39, P<0.01). Our study suggested D-dimer could be a potent marker to predict the mortality of COVID-19, which may be helpful for the management of patients.